Therapies targeting these pathways, such as ICIs (anti-PD-1 and anti-CTLA-4 antibodies), have shown promise in restoring T cell function and enhancing anti-tumor immunity (Marei et al., 2023; Kon and Benhar, 2019). Here, CTLA4 is linked to neoplasm.